Thank you for taking the time out of your busy day to read this Eblast. I wanted to make you aware of the new items we have uploaded to our HBV and HCV Advocate Web sites:
October 2010 HCV Advocate Newsletter:
Top-line results from the phase III trial of telaprevir, pegylated interferon and ribavirin to treat people who did not achieve an SVR with a previous course of pegylated interferon and ribavirin. You can also join me on-line for an HCV Advocate Video Update
on the trial results.
Disability and Benefits: Life Settlements (Cash for Your Life Insurance Policy) – read about the various types of life settlements, information about the potential benefits and downsides to cash in on insurance.
HealthWise: Finding Safety in Numbers by Lucinda Porter who discusses the changing landscape of HCV disease progression and some thoughts about what it means
HCV Snapshots – short recaps of some interesting studies about hepatitis C
SVR Reduces Risk of Death and Disease: Read about the very encouraging news about the benefits of achieving an SVR and even the benefits of just going HCV RNA undetectable while on HCV therapy.
HBV Journal Review:
Read about various issues and outcomes of HBV treatment, HBV transmission, Immunizations strategies, articles and other important information about HBV.
Be sure to check out the Herbal Dietary Supplements Glossary that we recently reviewed and updated.
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org
**Questions and Comments: Questions and/or comments can be directed to email@example.com
**To receive the eblast in your email inbox simply send an e-mail to: firstname.lastname@example.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.